Loading
Foundation Medicine's gene test for blood cancers such as leukaemia and lymphoma, which reads RNA as well as DNA so that it finds gene fusions.
FoundationOne Heme is Foundation Medicine's comprehensive genomic profiling test for blood cancers such as leukaemia and lymphoma. It sequences DNA from more than 400 genes and RNA from more than 250, which makes it suited to finding translocations and gene fusions, and every report gives the variant allele frequency of each finding. Foundation Medicine says its gene list includes the genes professional guidelines recommend testing in leukaemia and myelodysplastic syndromes. It accepts blood, bone marrow or a tissue biopsy, with a stated turnaround of 8 days. It is a laboratory-developed test that has not been reviewed or approved by the FDA, run in Foundation Medicine's CLIA-certified, CAP-accredited laboratories.
Next-generation sequencing of DNA from more than 400 genes and RNA from more than 250 genes, from blood, bone marrow or a tissue biopsy, detecting substitutions, insertions and deletions, copy number changes and gene fusions.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"FoundationOne Heme" OR ABSTRACT:"FoundationOne Heme") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FoundationOne Heme, not a curated reading list.
Shares FLT3-TKD (D835 and I836 tyrosine kinase domain mutations), KIT D816V, NPM1 mutation, FLT3-ITD (internal tandem duplication) and the tag test.
Shares Foundation Medicine (Roche), FoundationOne CDx / Liquid CDx, Next-generation sequencing (NGS) and the tag test.
Shares FLT3-TKD (D835 and I836 tyrosine kinase domain mutations), FLT3-ITD (internal tandem duplication) and the tag test.
Shares IDH2 mutation (R140 and R172), IDH1 R132 mutation, TP53 mutation and del(17p), Next-generation sequencing (NGS) and the tag test.
Shares IDH1 R132 mutation, Next-generation sequencing (NGS), Comprehensive genomic profiling and the tag test.
Shares Foundation Medicine (Roche), FoundationOne CDx / Liquid CDx and the tag test.
Shares KIT D816V and the tag test.
Shares Next-generation sequencing (NGS), Comprehensive genomic profiling and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/